Impact fund is investing millions in treating more people with light

The investment of 37 million Danish kroner will make it possible to introduce the Danish company Chromaviso’s lighting solutions to people with dementia, psychiatric patients and hospitalised people.

The European social impact fund Impact Partners has recently invested an amount in the million range in the Danish company Chromaviso, which provides circadian lighting solutions for hospitals and nursing homes in Scandinavia. The purpose of this investment is to realise the potential for even more patients and people suffering from dementia to be offered this new form of treatment, which has already proven to have a significant effect on the mental and physical health of patients.

”We are on the threshold of a new era in the use of circadian lighting in the health and nursing sector, and we are confident that Chromaviso will continue to be the natural leader in this field in the future. Their solutions have been documented through clinical studies and are based on highly specialised knowledge, which they have acquired through many years of work and innovative projects,” explains Managing Director Ulrik Fonsmark Andreasen, Impact Partners Nordic.

Synergy as the basis of investment
Impact Partners is currently establishing its sixth social impact fund, which they are going to invest in small and medium-sized companies helping marginalised citizens. The foundation set up offices in Denmark in the beginning of 2021, and the investment in Chromaviso will be the first investment in a Danish company.

”Chromaviso’s mission aligns with ours: to improve the lives of marginalised citizens. Their lighting technology improves the lives of people suffering from dementia as well as patients in psychiatric wards and hospitalised people. It is used to treat depression, anxiety and fatigue. Furthermore, their light helps reduce the stress of staff members, and improves their ability to concentrate – for example during laparoscopic surgery. And all this without side effects. This is a breakthrough in the field of mental health, and we are really looking forward to being a part of this journey,” explains Ulrik Fonsmark Andreasen.

Annually, more than 500,000 patients and people suffering from dementia are treated in Scandinavia with the company’s lighting solutions. The solutions created by Chromaviso are used by more and more places for treatment, most recently by the new Neurocentre at Copenhagen University Hospital. But this is just the beginning, as explained by co-founder and CEO Anders Kryger.

”The interest in integrating lighting solutions into major construction projects has increased significantly in recent years. Just like us, the new hospitals and nursing homes want the environment to be a factor in patient treatment and working environment. Our solution is prioritised as a safe choice, because it is based on evidence as well as experience. Furthermore, we have noticed how the clients who have used our circadian lighting for several years are starting to come back, wanting to expand the solution to larger areas or more wards.”

A fixed part of the environment
So far, Chromaviso has implemented lighting solutions in more than 2,500 projects at 130 hospitals and nursing homes throughout the Nordic countries.

”The market is ready, and so are we. Now that Impact is involved, we have the opportunity to increase the speed of our roll-out in the Nordic countries while continuing our long-term strategy of setting the highest standard for knowledge, evidence and technology. More people should experience the benefits of this light on health and quality of life, and it is our ambition for lighting to become a fixed part of the treatment environments – and not just in the Nordic countries,” says Anders Kryger.

According to Anders Kryger, the investment from Impact is to ensure the realisation of Chromaviso’s ambition to increase its turnover fivefold in the niche market of health in the Nordic countries, and in the long term in  Europe as well. Funds will be going towards scaling the business, including new innovation projects, increased digitalisation as well as intensification and internationalisation of the sales effort